3177 results for «365»

Filter By

3177 results

All you need to know about redo TAVI

15 Feb 2026 – From PCR Tokyo Valves 2026

This comprehensive session on redo Transcatheter Aortic Valve Implantation (TAVI) covers critical aspects beyond coronary obstruction risk, including detailed pre-procedural analysis, valve sizing, and innovative procedural techniques such as leaflet modification and optimal angle placement. Post-procedural considerations like antithrombotic therapy and patient-prosthesis mismatch are also thoroughly...

All you need to know about redo TAVI

Procedural imaging for tricuspid valve interventions

15 Feb 2026 – From PCR Tokyo Valves 2026

Dedicated to procedural imaging for tricuspid valve interventions, this session elucidates anatomical and pathophysiological features critical for successful transcatheter procedures. It emphasizes technical aspects of TEE and ICE imaging, including 3D multiplanar reconstruction, and offers case-based learning to refine imaging skills and optimize procedural outcomes.

Procedural imaging for tricuspid valve interventions

Miscellaneous complications: my worst nightmare

15 Feb 2026 – From PCR Tokyo Valves 2026

Explore the prevention and management of complications arising from transcatheter interventions in structural heart disease through challenging case analyses. This session presents real-world scenarios addressing complications encountered during TAVI, mitral, and tricuspid procedures, highlighting strategies to anticipate and manage these critical events effectively.

Miscellaneous complications: my worst nightmare

Transcatheter valve-in-valve intervention: LIVE Educational Case from The Prince Charles Hospital, Metro North Health - Brisbane, Australia

14 Feb 2026 – From PCR Tokyo Valves 2026

Review a live educational case from The Prince Charles Hospital focused on transcatheter valve-in-valve intervention, highlighting anatomical challenges, critical CT imaging roles, and meticulous planning to prevent complications and ensure favorable outcomes.

Transcatheter valve-in-valve intervention: LIVE Educational Case from The Prince Charles Hospital, Metro North Health - Brisbane, Australia

Late-breaking trials of PCR Tokyo Valves 2026

14 Feb 2026 – From PCR Tokyo Valves 2026

This session presents pivotal late-breaking trials from PCR Tokyo Valves 2026, offering one-year outcomes and real-world experiences in transcatheter valve therapies. Highlights include the AltaValve early feasibility study on atrial fixation TMVR, invasive registry insights on prosthesis-patient mismatch post-TAVR, and registry data on tricuspid and mitral...

Late-breaking trials of PCR Tokyo Valves 2026

PCR Tokyo Valves 2026 Welcome Ceremony

14 Feb 2026 – From PCR Tokyo Valves 2026

The Welcome Ceremony marks the commencement of the conference, setting the stage for an engaging and informative program dedicated to advances in cardiology and interventional techniques. It provides attendees with an overview of the event's objectives and highlights the collaborative spirit of the cardiology community.

Welcome Ceremony

Tricuspid: LIVE Educational Case from The Prince Charles Hospital, Metro North Health - Brisbane, Australia

14 Feb 2026 – From PCR Tokyo Valves 2026

This educational session from The Prince Charles Hospital in Brisbane offers a comprehensive live case demonstration of tricuspid TEER. It covers patient selection, procedural planning with multimodality imaging, step-by-step procedural strategies, and post-procedural assessment emphasizing echocardiographic evaluation and short-term outcomes.

Tricuspid: LIVE Educational Case from The Prince Charles Hospital, Metro North Health - Brisbane, Australia

Hot topics and evidence on structural interventions in 2025 and 2026

14 Feb 2026 – From PCR Tokyo Valves 2026

Delve into the emerging clinical evidence and key hot topics shaping transcatheter interventions for aortic, mitral, and tricuspid valve diseases anticipated to influence clinical practice in 2025 and 2026. This session reviews stroke prevention, valve interventions across the three valves, and integrates recent and upcoming data...

Hot topics and evidence on structural interventions in 2025 and 2026

Guidelines update

15 Feb 2026 – From PCR Tokyo Valves 2026

This session reviews the latest updates in the ESC/EACTS guidelines for structural heart disease, emphasizing their clinical implications and future trends. Participants will gain understanding of changes in aortic, mitral, and tricuspid valve recommendations, including new age cutoffs, asymptomatic disease management, and the evolving role of...

Guidelines update

Mitral TEER: LIVE Educational Case from Nagoya Heart Center - Nagoya, Japan

15 Feb 2026 – From PCR Tokyo Valves 2026

This session from Nagoya Heart Center provides an in-depth exploration of contemporary mitral Transcatheter Edge-to-Edge Repair (TEER), emphasizing the pivotal role of advanced imaging in transcatheter mitral interventions. It also discusses the available transcatheter treatment options tailored for complex mitral valve disease, featuring live case demonstrations,...

Mitral TEER: LIVE Educational Case from Nagoya Heart Center - Nagoya, Japan

Future devices and techniques for structural heart disease

15 Feb 2026 – From PCR Tokyo Valves 2026

This session surveys the future landscape of structural heart disease treatment, addressing current limitations in transcatheter valve technologies and presenting emerging devices and techniques for aortic, mitral, and tricuspid valves. Attendees will gain insights into innovations poised to transform therapeutic options for structural heart disease.

Future devices and techniques for structural heart disease

Transcatheter management of failed THV - LIVE case

09 Feb 2025 – From PCR Tokyo Valves 2025

An 84-year-old woman with diabetes mellitus, frailty (5/6), preserved LV function, and aortic stenosis previously treated with CoreValve 26 mm in 2016, presented with symptomatic degenerative stenosis of the valve.
A Sapien 3 (23 mm) was implanted without predilatation but with post-dilatation under general anaesthesia, using cerebral...

Transcatheter management of failed THV - LIVE case

Highlights of science and education in cardiovascular interventional medicine in 2025

22 Dec 2025

Dear Colleagues, dear PCR Companions,

As we welcome a New Year, it is the perfect time to reflect on what we achieved together over the past year - both as a celebration of our collective success and as motivation to continue improving in the year ahead.

2025 was...

PCRonline: Best of science & education in 2025

World Heart Day 2023: Reducing the burden of cardiovascular disease globally: beyond stents and balloons!

29 Sep 2023

Global burden of Cardiovascular Disease

Cardiovascular disease (CVD) remains the lead cause of mortality for men and women globally. Our world population in 2023 is 8 billion! Of these, around 620 million people are living with heart and circulatory diseases across the world. Each year around 60...

Vijay Kunadian

Author

Vijay Kunadian
World Heart Day 2023

The Lancet Commission to reduce global burden of cardiovascular disease in women by 2030

29 Aug 2021

Vijay Kunadian summarizes the key points of the LBT session of the ESC congress 2021 held on Sunday, 29 August focusing on the Lancet Commission to reduce the global burden of heart disease in women by 2030.

Vijay Kunadian

Author

Vijay Kunadian
ESC Congress 2021 - Global burden of cardiovascular disease in women; 20/20 vision for 2030: report of The Lancet commission

TRISCEND II trial: Randomized comparison of transcatheter valve replacement vs. optimal medical therapy for severe tricuspid regurgitation

04 Nov 2024

Alex Sticchi provides his take on the results of the TRISCEND II trial presented by Susheel K. Kodali and Suzanne V. Arnold at TCT 2024 in Washington.

Also watch the interview with Susheel K. Kodali

Alessandro Sticchi

Author

Alessandro Sticchi
TRISCEND II trial: Randomized comparison of transcatheter valve replacement vs. optimal medical therapy for severe tricuspid regurgitation

BRIGHT-4 – Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial

07 Nov 2022

Nicola Ryan provides her take on the BRIGHT-4 study, which was presented during AHA 2022 in Chicago, & simultaneously published in the Lancet.

This study was a randomised control trial designed to assess if bivalirudin plus a high dose infusion for 2-4 hours post PPCI was superior to unfractionated...

Nicola Ryan

Author

Nicola Ryan
BRIGHT-4 – Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial
Didn’t find what you were looking for?